Akari Therapeutics Plc (AKTX)
0.1301
-0.02
(-10.65%)
USD |
NASDAQ |
Mar 20, 16:00
0.1494
+0.02
(+14.83%)
After-Hours: 20:00
Akari Therapeutics Research and Development Expense (Quarterly) : 0.2474M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| DBV Technologies SA | 26.82M |
| Cellectis SA | -- |
| Biodexa Pharmaceuticals Plc | -- |
| Autolus Therapeutics Plc | 27.72M |
| Mereo BioPharma Group Plc | 4.187M |